Skip to main content
Supplement Research and Comparison WebsiteBest Price GuaranteeAbout Us
Supplement Research and Comparison Website

Oral administration of Bifidobacterium breve B-3 modifies metabolic functions in adults with obese tendencies in a randomised controlled trial

  • 2015
  • Journal of Nutritional Science 4
    • J. Minami
    • S. Kondo
    • N. Yanagisawa
    • T. Odamaki
    • J. Xiao
    • F. Abe
    • S. Nakajima
    • Yukie Hamamoto
    • Sanae Saitoh
    • T. Shimoda

Abstract

Accumulating evidence suggests an association between gut microbiota and the development of obesity, raising the possibility of probiotic administration as a therapeutic approach. Bifidobacterium breve B-3 was found to exhibit an anti-obesity effect on high-fat diet-induced obesity mice. In the present study, a randomised, double-blind, placebo-controlled trial was conducted to evaluate the effect of the consumption of B. breve B-3 on body compositions and blood parameters in adults with a tendency for obesity. After a 4-week run-in period, the participants were randomised to receive either placebo or a B-3 capsule (approximately 5 × 10(10) colony-forming units of B-3/d) daily for 12 weeks. A significantly lowered fat mass was observed in the B-3 group compared with the placebo group at week 12. Improvements were observed for some blood parameters related to liver functions and inflammation, such as γ-glutamyltranspeptidase and high-sensitivity C-reactive protein. Significant correlations were found between the changed values of some blood parameters and the changed fat mass in the B-3 group. These results suggest the beneficial potential of B. breve B-3 in improving metabolic disorders.

Keywords: Bifidobacterium; DIO, diet-induced obesity; HbA1c, glycated Hb; LPS, lipopolysaccharide; Metabolic syndrome; Obesity; Randomised controlled trials; hCRP, high-sensitivity C-reactive protein; γ-GTP, γ-glutamyltranspeptidase.

Research Insights

SupplementHealth OutcomeEffect TypeEffect Size
Bifidobacterium breveImproved Liver FunctionBeneficial
Moderate
Bifidobacterium breveReduced Body Fat MassBeneficial
Moderate
Bifidobacterium breveReduced Inflammation LevelsBeneficial
Moderate
Bifidobacterium breve Bb-03Improved Liver Function (γ-glutamyltranspeptidase)Beneficial
Small
Bifidobacterium breve Bb-03Reduced Body Fat MassBeneficial
Moderate
Bifidobacterium breve Bb-03Reduced High-Sensitivity C-Reactive ProteinBeneficial
Small
Bifidobacterium breve BBr60Improved Liver FunctionBeneficial
Moderate
Bifidobacterium breve BBr60Reduced Body Fat MassBeneficial
Moderate
Bifidobacterium breve BBr60Reduced Inflammation LevelsBeneficial
Moderate
Bifidobacterium breve BR-03Improved Liver FunctionBeneficial
Moderate
Bifidobacterium breve BR-03Reduced Body Fat MassBeneficial
Moderate
Bifidobacterium breve BR-03Reduced Inflammatory MarkersBeneficial
Small
Bifidobacterium breve BR03Improved Liver FunctionBeneficial
Moderate
Bifidobacterium breve BR03Improved Metabolic ParametersBeneficial
Moderate
Bifidobacterium breve BR03Reduced Body Fat MassBeneficial
Moderate
Bifidobacterium breve BR03Reduced Inflammation LevelsBeneficial
Moderate
Bifidobacterium breve MAK40B22BImproved Liver FunctionBeneficial
Moderate
Bifidobacterium breve MAK40B22BReduced Body Fat MassBeneficial
Moderate
Bifidobacterium breve MAK40B22BReduced Inflammatory MarkersBeneficial
Small
⬆ Back to top
Unsubscribe anytime. See our Privacy Policy.
Pillser
Supplement Research and Comparison Website: evidence-based information about supplements, their benefits, potential risks, and their efficacy.

Join Our Community

Statements on this website have not been reviewed by the U.S. Food and Drug Administration. These products are not meant to diagnose, treat, cure, or prevent any disease. The information here is not a replacement for personal medical advice.